JO
ATXI

John Overdeck’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

John Overdeck’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-191
Closed -$145K – 3124
2022
Q3 		$145K Buy
+191
New +$61.2K ﹤0.01% 2180

Other funds holding ATXI

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bayesian Capital Management Brooklyn, New York $156M AUM 14.89% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

John Overdeck's ATXI Position: Q4 2022 in Review

John Overdeck sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q4 2022, closing a stake of 191 shares — an estimated $145K sold.

John Overdeck first reported a position in ATXI in Q3 2022 and held it in 1 quarter. The position peaked at $145K in Q3 2022. 13 funds tracked by Wall St. Rank hold ATXI as of Q4 2022.

  • John Overdeck reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • John Overdeck sold 191 Avenue Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $145K.
  • John Overdeck first reported a position in Avenue Therapeutics, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • John Overdeck's Avenue Therapeutics, Inc. Common Stock position peaked at $145K in Q3 2022.
  • 13 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Two Sigma Investments's 13F filing for Q4 2022, filed 14 Feb 2023.